Brokerages predict that Alimera Sciences Inc (NASDAQ:ALIM) will report $12.25 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Alimera Sciences’ earnings, with estimates ranging from $12.00 million to $12.50 million. Alimera Sciences posted sales of $9.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 25%. The business is expected to announce its next earnings results on Thursday, May 2nd.
On average, analysts expect that Alimera Sciences will report full year sales of $55.18 million for the current year, with estimates ranging from $52.70 million to $57.65 million. For the next fiscal year, analysts anticipate that the business will report sales of $72.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Alimera Sciences.
ALIM has been the topic of a number of research analyst reports. HC Wainwright set a $2.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $2.44.
ALIM stock traded down $0.04 during trading on Friday, reaching $0.92. 84,064 shares of the company were exchanged, compared to its average volume of 100,849. The company has a market cap of $66.55 million, a P/E ratio of -3.17 and a beta of 2.22. Alimera Sciences has a 52-week low of $0.72 and a 52-week high of $1.21.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Further Reading: What are economic reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.